SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong third-quarter results, especially accelerating AI-compute revenue, sparked analyst upgrades and a bullish response. Traders also debated whether growth justifies the valuation, with heavy capital spending and an approaching share unlock cited as potential risks; Tesla merger discussions remain speculative.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings report beat profit expectations, but softer forward revenue guidance and a reduced advertising outlookalongside slowing growthtriggered a sharp selloff and renewed analyst downgrades. Traders are split between viewing the drop as evidence of tougher competition and weaker growth, and calling it an overreaction that creates a buying opportunity.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly outlook was sharply raised on strong AI-server demand, with gross-margin expectations also improving, sparking a sharp rally. Traders largely welcomed the update and argued the stock is undervalued, while others questioned whether margins, cash flow and execution can sustain the gains.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs spectrum acquisition and plans to expand Starlink Mobile have fueled concern that it could challenge AT&T and other wireless carriers, contributing to a sharp telecom selloff. Traders debate whether the threat is meaningful or years away, with bulls calling the drop an overreaction and pointing to AT&Ts fiber network and dividend.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders anticipate the 80th-event trigger and final analysis of its Phase 3 REGAL trial of GPS in AML, with recent trading gains fueling speculation about a near-term update and a possible short squeeze. Bullish buyout and positive-data theories are prominent, but skeptics note that no catalyst or outcome is confirmed and the trial results remain uncertain.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention centers on preliminary Phase 1 azer-cel results in progressive multiple sclerosis, with traders viewing the early safety and efficacy signals as a potential pipeline expansion beyond BRIUMVI while emphasizing that the study is small and needs confirmation. BRIUMVIs longer-term and commercial data also feature in the discussion, alongside mixed reactions to the stocks lack of sustained momentum.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

FDA approval of ORLADEYO oral pellets is drawing attention, with traders viewing the easier-to-administer formulation as a possible way to reach more HAE patients and improve tolerability. Some see incremental commercial potential, while others doubt it will meaningfully affect the share price amid continued frustration with BCRXs underperformance and management.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Speculation about possible U.S. regulatory relief for compounded peptides is a dominant topic, with bullish traders viewing access as a potential growth opportunity and skeptics emphasizing that approval is uncertain. The debate plays out alongside frustration over repeated rallies fading at resistance, while Hims German expansion adds to the growth discussion.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Analyst downgrades citing lackluster October momentum are weighing on Chipotle shares as traders look ahead to earnings amid concerns about slowing sales and margins. The community is split between expecting further declines and viewing the selloff as a buying opportunity.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives upsized SATS preferred offering to fund bitcoin purchases, together with warrant exercises, is driving debate over its financing strategy. Critics worry about dividend obligations, senior claims and dilution weighing on common shares, while bulls focus on the faster bitcoin accumulation the funding could enable.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADTX Stock Loses Nasdaq Listing After Seven Reverse Splits Fail To Restore Compliance: Why Is Retail Still Bullish? 

Equity

Nasdaq cited ADTX’s long stretch below the $1 minimum bid rule and a $35.17 million stockholders’ equity deficit.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session.
Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their outstanding shares isread more...

ADTX Stock Surges 40% Overnight: New 10% Holder Emerges After Aditxt’s Ignite Proteomics SPAC Deal 

The filing said the stake was acquired for investment purposes, with no current plan “to change or influence control” of Aditxt.

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers

Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regular session. The market value of their outstanding shares is at $4.0 million.
Aditxt (NASDAQ:ADTX) shares moved upwardsread more...

AI, Biotech, And Healthcare Catalysts Drive Momentum

Several emerging public companies are attracting attention as artificial intelligence, healthcare innovation, medical technology, and international commercialization strategies continue converging across the market. From AI-powered drug discovery and regenerative medicine expansion to precision dermatology and medical device innovation, recent developments highlight how smaller companies are positioning themselves around some of the fastest-growing sectors in healthcare and technology. $TGNT, $NXTS, $AZTR, $ADTX, $TNON, $PFE

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers

Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-market session. The company's market cap stands at $4.0 million.
Aditxt (NASDAQ:ADTX) shares rose 84.99% to $0.02.read more...

Nasdaq, S&P 500 Futures Surge As Wall Street Cheers US-Iran Deal, Brushes Off Hawkish Fed For Now: INTC, AAPL, MU, SPCX, RUM In Focus

Stocktwits data showed retail sentiment has improved to ‘bullish’ on SPY and QQQ from ‘bearish’ earlier in the week. 


Aditxt (ADTX) Stock Is Falling After Hours: What Is Going On?

Why Aditxt stock crashed after hours despite a new SEC filing showing Bank of America-linked share transactions.read more...

Aditxt (ADTX) Stock Surges Nearly 17% After Hours: Here's Why

Aditxt shares surged 16.92% after hours, extending intraday gains amid mixed SEC filing activity and corporate updates.read more...

ADTX Stock Rockets 90% Premarket: What's Fueling Rebound After A Record 22-Day Selloff?

Aditxt’s Ignite unit has signed a merger agreement with SPAC Copley Acquisition Corp. and is expected to become a standalone NYSE-listed company.

This account has been verified as an official ADTX representative.

Verified Account

Aditxt, Inc.

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Mountain View, CA.

Aditxt Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Aditxt shares are losing their Nasdaq listing after a panel rejected the company’s appeal over bid-price and stockholders’ equity failures.</li><li>Trading in ADTX common stock is set to be suspended at Thursday’s open, though the company can request a Nasdaq review within 15 days.</li><li>The panel was not persuaded by Aditxt’s proposed reverse split, noting that the company had already completed seven reverse splits.</li></ul>Shares of Aditxt, Inc. (ADTX) are losing their Nasdaq listing after a hearings panel rejected the company’s attempt to stay on the exchange, citing repeated failures to meet minimum bid price and stockholders’ equity requirements.<a href="https://stocktwits.com/symbol/ADTX">ADTX stock</a> crashed 77% on Wednesday and plunged another 19% in extended trading. Shares have shed nearly all of their value over the past year.<h2 class="st-heading-2">Nasdaq Pulls The Plug On ADTX</h2>Trading in ADTX common stock is set to be suspended at the open on Thursday, marking a major setback for the biotech company even as some retail traders bet on a potential comeback in OTC trading. Aditxt first received a Nasdaq delisting notice in May after its listed securities closed below the exchange’s $1 minimum bid price requirement for 30 straight business days, from March 24 through May 5.The company was not eligible for the usual 180-day compliance period as it had already carried out reverse stock splits over the past one and two years, including splits with a cumulative ratio of 250-to-1 or more. A second blow came later in May, when Nasdaq flagged Aditxt’s stockholders’ equity deficit of $35.17 million, far below the $2.5 million required for continued listing. The company also did not meet Nasdaq’s alternative standards based on market value or net income.Aditxt tried to keep its listing alive by laying out a recovery plan at a June 11 hearing, including another proposed reverse stock split at a ratio between 1-for-5 and 1-for-250. The company said it was targeting a post-split price of about $5. Nasdaq was not persuaded.The panel noted that Aditxt had already completed seven reverse stock splits, including a 1-for-113 split in November 2025, a 1-for-8 split in March and a 1-for-27 split last month. Even after these actions, the company failed to regain bid-price compliance. Nasdaq also noted that ADTX had closed below the $1 minimum bid price for about half of all trading days over the past two years. Aditxt may still request a review by Nasdaq’s Listing and Hearing Review Council within 15 days, though the company would have to pay a $15,000 review fee.&nbsp;<h2 class="st-heading-2">Ignite Deal Couldn’t Save ADTX Listing&nbsp;</h2>Aditxt’s biggest defense was Ignite Proteomics, its revenue-generating unit. Earlier this month, Aditxt signed a definitive agreement for Ignite to combine with Copley Acquisition Corp. in a deal valuing Ignite at about $150 million. The company said that the deal could increase stockholders’ equity by about $125 million and help it regain compliance by Sept. 15. It also said that Ignite could become an independent public company expected to trade on the NYSE, while Aditxt would continue as a separate listed company.But Nasdaq questioned the sharp valuation jump, the panel expressed skepticism over why Ignite, which Aditxt acquired in March for $35 million, had risen to a $150 million valuation within months. The panel also noted that, despite the clinical study cited by Aditxt and the Ignite deal, investors had not responded favorably to the company’s stock price.&nbsp;<h2 class="st-heading-2">ADTX Bulls Bet On OTC Comeback&nbsp;</h2>Despite the delisting decision, some retail traders are still leaning bullish, focusing on the possibility that ADTX could trade actively on the OTC market and that shareholders’ positions would carry over.On Stocktwits, retail sentiment for ADTX was ‘extremely bullish’ amid a 45,280% surge in message volumes over the past month. The ticker’s watcher base has also jumped 25% in the last three months.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/adtx_ss_png_45999676b0.webp" alt="adtx ss.png" width="972" height="131"><figcaption>ADTX sentiment and message volume as of June 25| Source: Stocktwits</figcaption></figure>One user called the shift to “PINK SHEETS” bullish,&nbsp;<a href="https://stocktwits.com/Ragnarok_74/message/657421517">saying</a>: “Yes! Very bullish now!” Another&nbsp;<a href="https://stocktwits.com/Gooo349/message/657420996">pointed</a> to Aditxt’s Nasdaq defense, saying that the company had claimed it could meet the $1 bid price and $2.5 million equity requirements by Sept.15.A third trader&nbsp;<a href="https://stocktwits.com/Drillerab1968/message/657411382">said</a> that OTC trading does not automatically mean the end of the story, writing: “The facts are just because it’s headed to the OTC isn’t the end of the world because your shares carry over.” The user cited the example of another company that traded OTC briefly and later returned to Nasdaq, saying: “The moral of the story there’s light at the end of the tunnel.”Meanwhile, a separate user&nbsp;<a href="https://stocktwits.com/Journey123098/message/657409235">said</a>: “I BOUGHT 50,000 SHARES RIGHT BEFORE CLOSING. THIS CAN GO UP HUGE IN OTC TOMORROW!”For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-worst-month-2026-hk-primary-listing-upgrade/cZ1GIzHR7Q1">NIO Stock Tracks Worst Month In 2026: EV Maker Pursues Hong Kong Primary Listing Upgrade To Expand Investor Base&nbsp;</a>

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.0008
Prev Close	$0.001
Open	$0.0006
Dividend Yield	0.00%
50-Day Moving Average	$0.0044
Beta	1.45
Avg. Volume	13.87M
PE Ratio	0.00

52-Week High	$8,125.42
52-Week Low	$0.0001
Market Capitalization	$798,381.00
EPS (Annual)	-$31,153.51
Price to Book	0.00
Revenue Per Employee	$122.89

Feed

News

Sentiment

Fundamentals

Info

ADTX Fundamentals